Drug Profile
SAB 301
Alternative Names: SAB-301Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator SAB Biotherapeutics
- Developer National Institutes of Health (USA)
- Class Antibodies; Antivirals; Monoclonal antibodies; Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Middle East respiratory syndrome coronavirus
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for phase-I development in Middle-East-respiratory-syndrome-coronavirus(In volunteers) in USA (IV)
- 10 Jan 2018 SAB Biotherapeutics completes a phase I trial for Middle East respiratory syndrome coronavirus infection (In volunteers) in USA (IV)
- 03 Aug 2017 SAB Biotherapeutics plans a phase II trial for Middle East respiratory syndrome coronavirus